Allovir Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
ALVR Nasdaq 8731 https://www.allovir.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Allovir Inc

AlloVir, Inc. (ALVR) Upgraded to Buy: Here's What You Should Know - Jan 25th, 2023 5:00 pm
How Much Upside is Left in AlloVir, Inc. (ALVR)? Wall Street Analysts Think 355.8% - Jan 25th, 2023 2:55 pm
Are Medical Stocks Lagging Adicet Bio (ACET) This Year? - Jan 25th, 2023 2:40 pm
AlloVir Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023 - Jan 9th, 2023 12:00 pm
AlloVir to Present at the 41st Annual J.P. Morgan Healthcare Conference - Jan 3rd, 2023 12:00 pm
AlloVir Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study In Oral Presentation at the 64th ASH Annual Meeting and Exposition - Dec 10th, 2022 10:15 pm
AlloVir to Participate in the Piper Sandler 34th Annual Healthcare Conference - Nov 15th, 2022 12:00 pm
Final Data from AlloVir’s Phase 2 Study of Posoleucel for Multi-Virus Prevention to be Highlighted in Oral Presentation at 64th American Society of Hematology Annual Meeting - Nov 3rd, 2022 1:07 pm
AlloVir Reports Third Quarter 2022 Financial Results - Nov 3rd, 2022 11:00 am
We Think AlloVir (NASDAQ:ALVR) Needs To Drive Business Growth Carefully - Oct 21st, 2022 12:30 pm
Wall Street Analysts See a 259% Upside in AlloVir, Inc. (ALVR): Can the Stock Really Move This High? - Sep 6th, 2022 1:55 pm
AlloVir to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference - Aug 31st, 2022 11:00 am
Does AlloVir, Inc. (ALVR) Have the Potential to Rally 251% as Wall Street Analysts Expect? - Aug 19th, 2022 1:55 pm
AlloVir Reports Second Quarter 2022 Financial Results - Aug 4th, 2022 11:00 am
Wall Street Analysts Predict a 447% Upside in AlloVir, Inc. (ALVR): Here's What You Should Know - Aug 3rd, 2022 1:55 pm
Do Institutions Own AlloVir, Inc. (NASDAQ:ALVR) Shares? - Aug 1st, 2022 12:09 pm
AlloVir Announces $126.6 Million Registered Direct Offering - Jul 27th, 2022 11:00 am
AlloVir's Posoleucel Shows Early Safety In Kidney Transplant Recipients - Jun 7th, 2022 4:07 pm
AlloVir Reports Blinded, Preliminary, Phase 2 Data Supporting the Ongoing Study of Posoleucel, a Multi-Virus-Specific T Cell Therapy, for the Treatment of BK Viremia in Kidney Transplant Recipients - Jun 7th, 2022 12:30 pm
AlloVir Reports First Quarter 2022 Financial Results - May 5th, 2022 11:00 am